Our leadership team has led the development of acoustic liquid handling technologies which have transformed the life sciences and biological research industries. Bringing together experience from other successful companies, our team possesses a broad range of experience and innovation. Leaders in biological research, members of our team are consistently at the forefront of the life sciences industry.
Mr. Fischer-Colbrie became president and CEO of Labcyte in September 2008. He has more than 30 years of experience in launching novel diagnostics, medical devices, therapeutics and high technology for growth companies, building from start-up through IPO and into high revenue levels.
Prior to joining Labcyte, Mr. Fischer-Colbrie was senior vice president of finance and administration and chief financial officer at Adeza Biomedical Corporation, a women’s health care start-up company, which went public in December 2004. The company was subsequently sold for $450 million. During his tenure at Adeza, Mr. Fischer-Colbrie was the inventor on 4 patents and 6 patent applications and led the business development function for three years. Mr. Fischer-Colbrie was senior vice president, finance and administration and chief financial officer for nearly nine years at a startup vision correction company that subsequently went public. Earlier in his career, he held several positions including vice-president, finance, corporate controller and advanced technology business manager at a manufacturer of disk drives that grew from a start up to $1.2 billion in revenue and also went public.
Mr. Fischer-Colbrie holds a B.A. from Stanford University and an M.B.A. in Marketing and Finance from the University of California at Berkeley. He is currently Chairman of the Board of the Juvenile Diabetes Research Foundation (JDRF). Mr. Fischer-Colbrie is also a board member of the Analytical, Life Science & Diagnostic Association (ALDA), an industry association. He was honored to be selected as National EY Entrepreneur Of The Year 2013 Life Sciences Finalist and Northern California EY Entrepreneur Of The Year 2013 Life Sciences Winner together with Rich Ellson, Labcyte CTO.
Mr. Ellson is a founder of Labcyte, formerly Picoliter Inc., where he serves as chief technology officer.
Before founding Labcyte in 2000, Mr. Ellson was area manager for novel printing technologies at the Xerox Palo Alto Research Center (PARC). Prior to joining PARC, he held a variety of management and technical roles at the Eastman Kodak Company in the fields of color printing, image data compression, fluid handling, materials transport and net-shape manufacturing applications. His contributions to internal manufacturing processes were acknowledged by a Kodak Doctoral Award in 1988. Mr. Ellson was nominated for the 1994 Lemelson-MIT Prize and is the inventor on more than 70 U.S. patents. He received the 2006 PolyPops Foundation Award from the Society for Biomolecular Sciences for his role in developing acoustic dispensing technology, the basis for the Labcyte Echo liquid handlers.
Mr. Ellson holds a B.S. in Fluid and Thermal Science and a M.S. in Mechanical Engineering from Case Western Reserve University. Through the Kodak Doctoral Awards Program, he took a two-year paid leave to study mathematics at the University of Illinois at Urbana-Champaign. He was honored to be selected as National EY Entrepreneur Of The Year 2013 Life Sciences Finalist and Northern California EY Entrepreneur Of The Year 2013 Life Sciences Winner together with Mark Fischer-Colbrie, Labcyte president and CEO.
Ms. Cameron has served as Labcyte’s Sr. Vice President of finance since 2011. She has more than 20 years of accounting and commercial financial experience at public and private companies.
Prior to joining Labcyte, Ms. Cameron served as vice president of finance at DepoMed Inc. from 2009 to 2011 and as the company’s controller from 2007 to 2009. She was also controller at Adeza Biomedical Corporation and was instrumental in bringing about its IPO and subsequent sale. Ms. Cameron was director of finance and administration at Timi3 Systems, a medical equipment company, for four years. Earlier in her career, she was director of treasury and external reporting at KeraVision, Inc. and was also a member of Ernst & Young's audit practice.
Ms. Cameron is a certified public accountant and holds a B.A. in Accounting from California State University, East Bay.
Mr. Grimley joined Labcyte in January 2015 and has more than 20 years of product marketing experience in the life science industry.
Before joining Labcyte, Mr. Grimley was the Vice President of Marketing at NanoString Technologies, Inc. from 2011 to 2015 during which time the company completed its IPO. Prior to that he served as Senior Director of Marketing at Agilent Technologies, where he headed marketing for the company’s genomics portfolio which included the company’s microarray, target enrichment and molecular biology reagents product lines. Mr. Grimley began his career in the life science business at Applied Biosystems (now part of Thermo Fisher Scientific) where from 1994 to 2008 he held positions of increasing responsibility including Director of Marketing for the company’s real-time PCR instrument portfolio.
Mr. Grimley holds a Bachelor of Science degree in Biochemistry from San Francisco State University
Mr. Lasinski joined Labcyte in 2008, bringing more than 20 years' experience in the life science industry in sales roles of increasing responsibility. Previously he was Director, North American Sales and Global Key Accounts at Codon Devices from 2007-2008. Prior, he held various sales positions at Applied Biosystems (now part of Thermo Fischer Scientific) from 1992-2007 leading up to his role as Sales Director, including Director of Pharmaceutical Sales focused on top global pharmaceutical accounts.
Mr. Lasinski received a BA in biochemistry from Rutgers University, New Brunswick.
Mr. Love has more than 25 years of leadership experience at biotechnology, telecom, specialty materials, equipment and semiconductor companies.
Mr. Love was most recently general manager/vice president of operations at InLight Communications, a telecom start up that develops optical micro-electromechanical system (MEMS) solutions. Prior to that, Mr. Love was vice president of operations for Synteni, a biotech start up that merged with Incyte Genomics. Earlier in his career, Mr. Love spent eight years as general manager for Heraeus, a leading supplier to semiconductor equipment manufacturers and end users, where he had overall responsibility for the company’s largest and most profitable division.
Mr. Love holds a B.S. in Mechanical Engineering with honors from the University of Illinois at Urbana-Champaign.
Mr. Miller joined Labcyte in 2002 and has more than 30 years of experience in engineering and management. He brings this expertise to his product development role at Labcyte.
Before joining Labcyte, Mr. Miller was department director, Genomics Systems Development and a member of the Amersham Biosciences senior management team in Sunnyvale, CA. While at Molecular Dynamics, which was acquired by Amersham, he was director of product development and manager of mechanical engineering. He was instrumental in the successful introduction of a number of products including the PhosphorImager, FluorImager and Storm imaging systems and the MegaBACE DNA sequencer. Earlier in his career, he held various management and technical positions at Spectra-Physics (now part of Newport Corporation), a supplier of solutions for precision laser applications.
Mr. Miller is an inventor on eight U. S. patents and holds a B.S. in Mechanical Engineering cum laude from San Jose State University.
Dr. Keegan has more than 30 years of experience in life science businesses. Most recently as CEO at ForteBio, Inc. he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45%, and exited the company through its sale to Pall Corporation at 6x ttm revenue. During his 9 year tenure at Molecular Devices Corporation, Dr. Keegan grew the company's revenues from $30M to $200M through internal growth and acquisitions. In early 2007, he oversaw its acquisition by MDS for $615M. Dr. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was Vice President of the Microscopy and Scientific Instruments Division of Leica, Inc. He currently serves on the Board of Directors of Arrayjet LTD, Bio-Techne (NASDAQ:TECH), Carterra, Halo Labs, Interpace Diagnostics (NASDAQ:IDXG), and Nanomedical Diagnostics as Executive Chairman. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.
Sandra Panem, Ph.D. is a partner of Cross Atlantic Partners, a venture capital firm focused on the emerging life sciences and health care industry. She has 30 years of experience in the life sciences encompassing private and public equity portfolio management, venture capital, scientific research, and public policy. Dr. Panem received a B.S. Degree in Biochemistry and a Ph.D. in Microbiology from the University of Chicago. She was President of Vector Fund Management, a private equity fund investing in the emerging life sciences and healthcare industries. Prior to joining Vector, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a mutual fund that invested in public and private life science companies. Prior to Oppenheimer, Dr. Panem was Vice President at Salomon Brothers, Inc. where she was a principal member of the investment team responsible for Salomon Brothers Venture Capital. Dr. Panem was also an Assistant Professor of Pathology at the University of Chicago, and a Science and Public Policy Fellow in Economic Studies at the Brookings Institution. She is the author of several books concerning the commercialization of new medical technologies. Dr. Panem has served as a member of numerous Boards of public and private companies, as well as non-profit organizations.
Mr. Smith has over 30 years of business and legal experience and is currently Sr. Vice President, Business Development and General Counsel of Cepheid, a leading developer of integrated systems for genetic assessment. He was previously Senior Vice President, Business Development, at Applied Biosystems group of Applera Corporation. In that capacity he directed the activities of Applied Biosystems in scouting and closing new business opportunities and investments, potential acquisitions, mergers, and collaborations. Prior to his post as the head of business development at Applied Biosystems Group, Mr. Smith was Assistant Secretary of Applera Corporation (1998-2002) and Vice President of Intellectual Property for Applied Biosystems Group (ABI) and its predecessor, PE Biosystems Division of Perkin-Elmer (1995-2001), and Vice President of Intellectual Property for Applied Biosystems, Inc. (1989-1994), the predecessor of PE Biosystems. During that time, Mr. Smith and his team built the patent portfolio from a handful of patents and applications to over 400. He was also responsible for designing an out-licensing strategy for the company, implementing a highly successful worldwide patent licensing program for PCR thermal cyclers, PCR reagents, and DNA sequencing.
Prior to his activities with Applied Biosystems, Mr. Smith was a partner at the intellectual property law firm of Wiseman, Jones, and Smith, and the law firm of Boone, Fox, and Jones, and was a member of the technical legal department of Hewlett-Packard. Mr. Smith holds a B.S. in Engineering Physics from the University of Arizona; an M.S. in Physics and a C. Phil. in Theoretical Physics from the University of California, San Diego, and a Juris Doctorate from Santa Clara University.
Mr. Taylor has been an active venture capitalist since 1977. He earned a B.S. (1972) and an M.S. (1974) in Physics from Brown University, and an M.B.A. from Stanford in 1977. He worked in the Office of Technology Licensing at Stanford from 1975 to 1977. In addition to Labcyte Inc., he serves on the boards of several private companies, including KFx Medical, Optimedica and Zyomyx. Mr. Taylor is a past member of the Board of Directors of the National Venture Capital Association, and serves as an advisor to Astia.
EN